摘要
[目的]观察MVP化疗方案治疗非小细胞肺癌 (NSCLC)对血清肿瘤标记物 (TM)癌胚抗原 (CEA)、CYFRA21_1、神经烯醇酶(NSE)和血清一氧化氮 (NO)的影响。[方法]84例诊断明确的NSCLC患者采用MVP(MMC、VDS、DDP)联合化疗 ,化疗前后测定血清TM(CEA、CYFRA21_1、NSE)和NO。[结果]CR0,PR36例 (42.9 % )、SD38例 (45.2% ),PD10例 (11.9% )。PR和SD组患者血清NO均较化疗前明显增高 (P<0.05～0.01) ,PD组有降低趋势 ,但统计学上无明显差异 (P>0.05)。PR和SD组患者血清CEA和CYFRA21_1均较化疗前明显降低 (P<0.05～0.01) ,PD组有增高趋势 ,但统计学上无明显差异 (P>0.05)。血清NSE则无明显改变 (P>0.05)。[结论]MVP化疗后有效者TM指标明显下降 ,血清NO则明显上升。血清TM和NO的变化有助于对肺癌患者疗效的评价。
To observe the impact of chemotherapy on serum tumor markers such as CEA, CYFRA21_1, NSE and nitrogen monoxide (NO)in patients with non_small cell lung cancer (NSCLC) .Eighty_four NSCLC patients were treated with the combined chemotherapy regimen MVP (MMC,VDS,DDP) and tested serum TM (CEA, CYFRA21_1, NSE) and NO before and after chemotherapy. There were 36 cases of PR (42.9%), 38 cases of SD (45.2%), and 10 cases of PD(11.9%). The value of serum NO in PR and SD groups were much higher than that before chemotherapy (P<0.05～0.01) and the value in PD group was decreased, but there was no significant difference (P>0.05). The value of serum CEA and CYFRA21_1 in PR and SD groups were much lower than that before chemotherapy (P<0.05～0.01) and the value in PD group was increased, but there was no significant difference (P>0.05). There was no significant difference in serum NSE (P>0.05). [Conclusion] TM values significantly decrease in the patients treated with MVP regimen, while serum NO increases. The change of serum TM and NO is helpful for assessing effect in lung cancer patients.
出处
《肿瘤学杂志》
CAS
2002年第4期213-214,共2页
Journal of Chinese Oncology
